{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:15:20Z","timestamp":1772712920156,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372896"],"award-info":[{"award-number":["82372896"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Foundation of Cancer Biology State Key Laboratory","award":["CBSKL2022ZDKF12"],"award-info":[{"award-number":["CBSKL2022ZDKF12"]}]},{"name":"Key Scientific Research Foundation of Henan Educational Committee","award":["24A310018"],"award-info":[{"award-number":["24A310018"]}]},{"name":"Key Research and Development Project of Henan Province","award":["231111311900"],"award-info":[{"award-number":["231111311900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-025-05442-5","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:35:50Z","timestamp":1765528550000},"page":"1011-1028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer"],"prefix":"10.1007","volume":"481","author":[{"given":"Yan","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haodi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hehe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-dong","family":"Cang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"5442_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"5442_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG (2021) Prostate cancer. Lancet 398:1075\u20131090","journal-title":"Lancet"},{"issue":"12","key":"5442_CR3","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/cells9122653","volume":"9","author":"G Aurilio","year":"2020","unstructured":"Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R (2020) Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells 9(12):2653","journal-title":"Cells"},{"key":"5442_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L (2019) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 22:24\u201338","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5442_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","volume":"23","author":"L Chen","year":"2024","unstructured":"Chen L, Xu YX, Wang YS, Ren YY, Dong XM, Wu P, Xie T, Zhang Q, Zhou JL (2024) Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Mol Cancer 23:229","journal-title":"Mol Cancer"},{"key":"5442_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y (2024) Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett 601:217155","journal-title":"Cancer Lett"},{"key":"5442_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan NP (2023) Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach. Cell Rep Med 4:101199","journal-title":"Cell Rep Med"},{"issue":"5","key":"5442_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051145","volume":"13","author":"EG Shackleton","year":"2021","unstructured":"Shackleton EG, Ali HY, Khan M, Pockley GA, McArdle SE (2021) Novel combinatorial approaches to tackle the immunosuppressive microenvironment of prostate cancer. Cancers (Basel) 13(5):1145","journal-title":"Cancers (Basel)"},{"key":"5442_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41568-021-00377-7","volume":"21","author":"G Koh","year":"2021","unstructured":"Koh G, Degasperi A, Zou X, Momen S, Nik-Zainal S (2021) Mutational signatures: emerging concepts, caveats and clinical applications. Nat Rev Cancer 21:619\u2013637","journal-title":"Nat Rev Cancer"},{"key":"5442_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN et al (2020) The repertoire of mutational signatures in human cancer. Nature 578:94\u2013101","journal-title":"Nature"},{"key":"5442_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/em.22215","volume":"59","author":"N Saini","year":"2018","unstructured":"Saini N, Gordenin DA (2018) Somatic mutation load and spectra. A record of DNA damage and repair in healthy human cells. Environ Mol Mutagen 59:672\u2013686","journal-title":"Environ Mol Mutagen"},{"key":"5442_CR12","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1038\/s41467-024-45909-5","volume":"15","author":"A Sanchez","year":"2024","unstructured":"Sanchez A, Ortega P, Sakhtemani R, Manjunath L, Oh S, Bournique E, Becker A, Kim K, Durfee C, Temiz NA et al (2024) Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes. Nat Commun 15:2370","journal-title":"Nat Commun"},{"key":"5442_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton C, McGranahan N, Starrett GJ, Harris RS (2015) APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 5:704\u2013712","journal-title":"Cancer Discov"},{"key":"5442_CR14","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1158\/0008-5472.CAN-15-2171-T","volume":"75","author":"B Leonard","year":"2015","unstructured":"Leonard B, McCann JL, Starrett GJ, Kosyakovsky L, Luengas EM, Molan AM, Burns MB, McDougle RM, Parker PJ, Brown WL et al (2015) The PKC\/NF-kappaB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res 75:4538\u20134547","journal-title":"Cancer Res"},{"key":"5442_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3892\/br.2014.256","volume":"2","author":"H Sasaki","year":"2014","unstructured":"Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaka Y, Okuda K, Moriyama S, Yano M, Fujii Y (2014) APOBEC3B gene overexpression in non-small-cell lung cancer. Biomed Rep 2:392\u2013395","journal-title":"Biomed Rep"},{"key":"5442_CR16","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1158\/0008-5472.CAN-13-1753","volume":"73","author":"B Leonard","year":"2013","unstructured":"Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL et al (2013) APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res 73:7222\u20137231","journal-title":"Cancer Res"},{"key":"5442_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB et al (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366\u2013370","journal-title":"Nature"},{"key":"5442_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41588-023-01504-w","volume":"55","author":"JL McCann","year":"2023","unstructured":"McCann JL, Cristini A, Law EK, Lee SY, Tellier M, Carpenter MA, Beghe C, Kim JJ, Sanchez A, Jarvis MC et al (2023) APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer. Nat Genet 55:1721\u20131734","journal-title":"Nat Genet"},{"key":"5442_CR19","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/ng.2736","volume":"45","author":"KJ Kuong","year":"2013","unstructured":"Kuong KJ, Loeb LA (2013) APOBEC3B mutagenesis in cancer. Nat Genet 45:964\u2013965","journal-title":"Nat Genet"},{"key":"5442_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/ng.2701","volume":"45","author":"MB Burns","year":"2013","unstructured":"Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45:977\u2013983","journal-title":"Nat Genet"},{"key":"5442_CR21","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.7150\/thno.73235","volume":"12","author":"R Shi","year":"2022","unstructured":"Shi R, Wang X, Wu Y, Xu B, Zhao T, Trapp C, Wang X, Unger K, Zhou C, Lu S et al (2022) APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases. Theranostics 12:4181\u20134199","journal-title":"Theranostics"},{"key":"5442_CR22","doi-asserted-by":"publisher","first-page":"1975386","DOI":"10.1080\/2162402X.2021.1975386","volume":"10","author":"S Xia","year":"2021","unstructured":"Xia S, Gu Y, Zhang H, Fei Y, Cao Y, Fang H, Wang J, Lin C, Zhang H, Li H et al (2021) Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. Oncoimmunology 10:1975386","journal-title":"Oncoimmunology"},{"key":"5442_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-21-0146","volume":"10","author":"AV DiMarco","year":"2022","unstructured":"DiMarco AV, Qin X, McKinney BJ, Garcia NMG, Van Alsten SC, Mendes EA, Force J, Hanks BA, Troester MA, Owzar K et al (2022) APOBEC mutagenesis inhibits breast cancer growth through induction of T cell-mediated antitumor immune responses. Cancer Immunol Res 10:70\u201386","journal-title":"Cancer Immunol Res"},{"key":"5442_CR24","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28:1747\u20131756","journal-title":"Genome Res"},{"key":"5442_CR25","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1002\/jcb.25117","volume":"116","author":"Y Guo","year":"2015","unstructured":"Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, Yi R, Xie X, Yao L, Liu W et al (2015) Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. J Cell Biochem 116:2465\u20132475","journal-title":"J Cell Biochem"},{"key":"5442_CR26","doi-asserted-by":"publisher","first-page":"11056","DOI":"10.1093\/nar\/gkx721","volume":"45","author":"M Periyasamy","year":"2017","unstructured":"Periyasamy M, Singh AK, Gemma C, Kranjec C, Farzan R, Leach DA, Navaratnam N, Palinkas HL, Vertessy BG, Fenton TR et al (2017) p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. Nucleic Acids Res 45:11056\u201311069","journal-title":"Nucleic Acids Res"},{"key":"5442_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C (2021) Cytokine regulation and function in T cells. Annu Rev Immunol 39:51\u201376","journal-title":"Annu Rev Immunol"},{"key":"5442_CR28","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542\u2013551","journal-title":"Lancet Oncol"},{"key":"5442_CR29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G et al (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45:970\u2013976","journal-title":"Nat Genet"},{"key":"5442_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL et al (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421","journal-title":"Nature"},{"key":"5442_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13578-017-0156-4","volume":"7","author":"J Zou","year":"2017","unstructured":"Zou J, Wang C, Ma X, Wang E, Peng G (2017) APOBEC3B, a molecular driver of mutagenesis in human cancers. Cell Biosci 7:29","journal-title":"Cell Biosci"},{"key":"5442_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12859-022-04862-0","volume":"23","author":"J Wu","year":"2022","unstructured":"Wu J, Li N, Zhu L, Zhen D, Li M, Chen H, Ye M, Wei Y, Shao G (2022) Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis. BMC Bioinformatics 23:312","journal-title":"BMC Bioinformatics"},{"key":"5442_CR33","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1177\/1636.17922","volume":"100","author":"M Gwak","year":"2014","unstructured":"Gwak M, Choi YJ, Yoo NJ, Lee S (2014) Expression of DNA cytosine deaminase APOBEC3 proteins, a potential source for producing mutations, in gastric, colorectal and prostate cancers. Tumori 100:e112\u2013117","journal-title":"Tumori"},{"key":"5442_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.10.016","volume":"34","author":"C Gerhauser","year":"2018","unstructured":"Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hubschmann D et al (2018) Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories. Cancer Cell 34:e996-1011","journal-title":"Cancer Cell"},{"key":"5442_CR35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/mc.22956","volume":"58","author":"W Ma","year":"2019","unstructured":"Ma W, Ho DW, Sze KM, Tsui YM, Chan LK, Lee JM, Ng IO (2019) APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. Mol Carcinog 58:643\u2013653","journal-title":"Mol Carcinog"},{"issue":"6","key":"5442_CR36","doi-asserted-by":"publisher","first-page":"e02234","DOI":"10.1128\/mBio.02234-14","volume":"5","author":"VC Vieira","year":"2014","unstructured":"Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, Lee D, Soares MA, Lambert PF, Howley PM et al (2014) Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. mBio 5(6):e02234\u2013e02214","journal-title":"mBio"},{"key":"5442_CR37","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41418-022-00989-y","volume":"29","author":"MC Kennedy","year":"2022","unstructured":"Kennedy MC, Lowe SW (2022) Mutant p53: it\u2019s not all one and the same. Cell Death Differ 29:983\u2013987","journal-title":"Cell Death Differ"},{"key":"5442_CR38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/abbs\/gmt144","volume":"46","author":"J Liu","year":"2014","unstructured":"Liu J, Zhang C, Feng Z (2014) Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) 46:170\u2013179","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"5442_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.02.028","volume":"26","author":"N Roper","year":"2019","unstructured":"Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown AL et al (2019) APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors. Cell Rep 26:e2651-2656","journal-title":"Cell Rep"},{"key":"5442_CR40","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41467-020-14568-7","volume":"11","author":"CB Driscoll","year":"2020","unstructured":"Driscoll CB, Schuelke MR, Kottke T, Thompson JM, Wongthida P, Tonne JM, Huff AL, Miller A, Shim KG, Molan A et al (2020) APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat Commun 11:790","journal-title":"Nat Commun"},{"key":"5442_CR41","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-15-2910","volume":"22","author":"B Leonard","year":"2016","unstructured":"Leonard B, Starrett GJ, Maurer MJ, Oberg AL, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM et al (2016) APOBEC3G expression correlates with T-cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma. Clin Cancer Res 22:4746\u20134755","journal-title":"Clin Cancer Res"},{"key":"5442_CR42","doi-asserted-by":"publisher","first-page":"e1421891","DOI":"10.1080\/2162402X.2017.1421891","volume":"7","author":"EJ Crosby","year":"2018","unstructured":"Crosby EJ, Wei J, Yang XY, Lei G, Wang T, Liu CX, Agarwal P, Korman AJ, Morse MA, Gouin K et al (2018) Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology 7:e1421891","journal-title":"Oncoimmunology"},{"issue":"12","key":"5442_CR43","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cancers14122827","volume":"14","author":"H Guo","year":"2022","unstructured":"Guo H, Zhu L, Huang L, Sun Z, Zhang H, Nong B, Xiong Y (2022) APOBEC alteration contributes to tumor growth and immune escape in pan-cancer. Cancers (Basel) 14(12):2827","journal-title":"Cancers (Basel)"},{"key":"5442_CR44","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","volume":"37","author":"S Wang","year":"2018","unstructured":"Wang S, Jia M, He Z, Liu XS (2018) APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene 37:3924\u20133936","journal-title":"Oncogene"},{"key":"5442_CR45","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1136\/gutjnl-2018-317601","volume":"68","author":"D Wang","year":"2019","unstructured":"Wang D, Li X, Li J, Lu Y, Zhao S, Tang X, Chen X, Li J, Zheng Y, Li S et al (2019) APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut 68:1846\u20131857","journal-title":"Gut"},{"key":"5442_CR46","doi-asserted-by":"publisher","first-page":"e2408598","DOI":"10.1002\/advs.202408598","volume":"11","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Wu Y, Zhao B, Shen Z, Hu S, Zhang C, Zhang X, Zhang J et al (2024) Blockade of CCR5(+) T cell accumulation in the tumor microenvironment optimizes Anti-TGF-beta\/PD-L1 bispecific antibody. Adv Sci (Weinh) 11:e2408598","journal-title":"Adv Sci (Weinh)"},{"issue":"16","key":"5442_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165647","volume":"21","author":"J Korbecki","year":"2020","unstructured":"Korbecki J, Kojder K, Barczak K, Siminska D, Gutowska I, Chlubek D, Baranowska-Bosiacka I (2020) Hypoxia alters the expression of CC chemokines and CC chemokine receptors in a tumor-a literature review. Int J Mol Sci 21(16):5647","journal-title":"Int J Mol Sci"},{"key":"5442_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/intimm\/dxu079","volume":"27","author":"O Yoshie","year":"2015","unstructured":"Yoshie O, Matsushima K (2015) CCR4 and its ligands: from bench to bedside. Int Immunol 27:11\u201320","journal-title":"Int Immunol"},{"key":"5442_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1299953","volume":"14","author":"Z Dai","year":"2023","unstructured":"Dai Z, Wang Y, Sun N, Zhang C (2023) Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma. Front Immunol 14:1299953","journal-title":"Front Immunol"},{"key":"5442_CR50","doi-asserted-by":"publisher","first-page":"13288","DOI":"10.1038\/s41598-019-49613-z","volume":"9","author":"MJ Kim","year":"2019","unstructured":"Kim MJ, Sun HJ, Song YS, Yoo SK, Kim YA, Seo JS, Park YJ, Cho SW (2019) CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer. Sci Rep 9:13288","journal-title":"Sci Rep"},{"key":"5442_CR51","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41423-018-0019-x","volume":"15","author":"XQ Wang","year":"2018","unstructured":"Wang XQ, Zhou WJ, Hou XX, Fu Q, Li DJ (2018) Trophoblast-derived CXCL16 induces M2 macrophage polarization that In turn inactivates NK cells at the maternal-fetal interface. Cell Mol Immunol 15:1038\u20131046","journal-title":"Cell Mol Immunol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05442-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05442-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05442-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:17:22Z","timestamp":1772709442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05442-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["5442"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05442-5","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Studies using human tissues were approved by the Human Research Ethics Committees of Shanghai Outdo Biotech Company (Shanghai, China, SHYJS-CP-1907004) in agreement with the guidelines set forth by the Declaration of Helsinki. Written informed consent was obtained from all patients whose tissues were used in this study. Studies on animals were conducted in accordance with relevant guidelines and regulations and were approved by the Animal Research Ethics Committee of Zhengzhou University (Zhengzhou, China; ZZU-LAC20220910).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All contributors have agreed to publish this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}